Format
Sort by
Items per page

Send to

Choose Destination

Best matches for MELPHALAN/AE:

Oral melphalan for the treatment of relapsed canine lymphoma. Mastromauro ML et al. Vet Comp Oncol. (2018)

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma. Zweegman S et al. Blood. (2016)

Encephalopathy following melphalan administration. Dubey D et al. J Chemother. (2017)

Search results

Items: 1 to 20 of 1351

1.

BAM conditioning before autologous transplantation for lymphoma: a study on behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC).

Cornillon J, Daguenet E, Bay JO, Chauchet A, Salles G, Contentin N, Nicolas-Virelizier E, Mercier M, Vallet N, Alexis M, Chrétien ML, Cluzeau T, Huynh A, Himberlin C, Dorvaux V, Amorim S, Lejeune C, de Latour RP, Gyan E.

Ann Hematol. 2019 Aug;98(8):1973-1980. doi: 10.1007/s00277-019-03704-z. Epub 2019 May 20.

PMID:
31111177
2.

Therapy-related myeloid neoplasms after treatment for plasma-cell disorders.

Chung A, Liedtke M.

Best Pract Res Clin Haematol. 2019 Mar;32(1):54-64. doi: 10.1016/j.beha.2019.02.003. Epub 2019 Feb 8. Review.

PMID:
30927976
3.

Rabbit Model of Intra-Arterial Chemotherapy Toxicity Demonstrates Retinopathy and Vasculopathy Related to Drug and Dose, Not Procedure or Approach.

Daniels AB, Froehler MT, Nunnally AH, Pierce JM, Bozic I, Stone CA, Santapuram PR, Tao YK, Boyd KL, Himmel LE, Chen SC, Du L, Friedman DL, Richmond A.

Invest Ophthalmol Vis Sci. 2019 Mar 1;60(4):954-964. doi: 10.1167/iovs.18-25346.

4.

High rates of ovarian function preservation after hematopoietic cell transplantation with melphalan-based reduced intensity conditioning for pediatric acute leukemia: an analysis from the Japan Association of Childhood Leukemia Study (JACLS).

Fujino H, Ishida H, Iguchi A, Onuma M, Kato K, Shimizu M, Yasui M, Fujisaki H, Hamamoto K, Washio K, Sakaguchi H, Miyashita E, Osugi Y, Nakagami-Yamaguchi E, Hayakawa A, Sato A, Takahashi Y, Horibe K.

Int J Hematol. 2019 May;109(5):578-583. doi: 10.1007/s12185-019-02627-9. Epub 2019 Mar 12.

PMID:
30864117
5.

Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients.

Xue K, Ren H, Meng F, Zhang R, Qian J.

BMC Ophthalmol. 2019 Feb 26;19(1):61. doi: 10.1186/s12886-019-1059-4.

6.

Modified BuCy is an alternative conditioning regimen for lymphoma patients undergoing autologous stem cell transplantation.

Huang H, Zhang L, Jiang Y, Liu S, Jin Z, Chen J, Xiao X, Ruan J, Zhang X, Wu D.

Ann Hematol. 2019 May;98(5):1259-1266. doi: 10.1007/s00277-018-3576-2. Epub 2019 Jan 12.

PMID:
30635767
7.

Response and Toxicity of Repeated Isolated Limb Perfusion (re-ILP) for Patients With In-Transit Metastases of Malignant Melanoma.

Belgrano V, Pettersson J, Nilsson JA, Mattsson J, Katsarelias D, Olofsson Bagge R.

Ann Surg Oncol. 2019 Apr;26(4):1055-1062. doi: 10.1245/s10434-018-07143-4. Epub 2019 Jan 7.

8.

A Single Nucleotide Polymorphism in SLC7A5 Was Associated With Clinical Response in Multiple Myeloma Patients.

Poi MJ, Li J, Johnson JA, Cho YK, Sborov DW, Phelps MA, Hofmeister CC.

Anticancer Res. 2019 Jan;39(1):67-72. doi: 10.21873/anticanres.13080.

PMID:
30591441
9.

Prevention of chemotherapy-induced nausea and vomiting after high-dose melphalan and stem cell transplantation: review of the evidence and suggestions.

Tendas A, Marchesi F, Mengarelli A, Annibali O, Tomarchio V, Saltarelli D, Chierichini A, Di Venanzio M, Sollazzo F, Piedimonte M, Cupelli L, Bruno A, De Angelis G, Delbono L, Niscola P, Perrotti AP, de Fabritiis P, Arcese W; Rome Transplant Network.

Support Care Cancer. 2019 Mar;27(3):793-803. doi: 10.1007/s00520-018-4594-2. Epub 2018 Dec 18. Review.

PMID:
30564934
10.

Intra-arterial chemotherapy for unilateral advanced intraocular retinoblastoma: Results and short-term complications.

Wang L, Han M, Zhao J, Wu C, Wang Z, Li J, Song D, Wang C, Yang Y, Guo L.

Medicine (Baltimore). 2018 Oct;97(42):e12676. doi: 10.1097/MD.0000000000012676.

11.

Atypical bortezomib-induced neutrophilic dermatosis.

Lescoat A, Dupuy A, Belhomme N, Stock N, Sebillot M, Decaux O, Jégo P, Droitcourt C.

Ann Hematol. 2019 May;98(5):1315-1316. doi: 10.1007/s00277-018-3519-y. Epub 2018 Oct 12. No abstract available.

PMID:
30315343
12.

Percutaneous hepatic perfusion (chemosaturation) with melphalan in patients with intrahepatic cholangiocarcinoma: European multicentre study on safety, short-term effects and survival.

Marquardt S, Kirstein MM, Brüning R, Zeile M, Ferrucci PF, Prevoo W, Radeleff B, Trillaud H, Tselikas L, Vicente E, Wiggermann P, Manns MP, Vogel A, Wacker FK.

Eur Radiol. 2019 Apr;29(4):1882-1892. doi: 10.1007/s00330-018-5729-z. Epub 2018 Sep 25.

PMID:
30255257
13.

Dose-intensified bendamustine and melphalan (BenMel) conditioning before second autologous transplantation in myeloma patients.

Farag S, Jeker B, Bacher U, Mansouri Taleghani B, Mueller BU, Novak U, Pabst T.

Hematol Oncol. 2018 Oct;36(4):671-678. doi: 10.1002/hon.2546. Epub 2018 Sep 11.

PMID:
30110717
14.

Resource utilization and toxicities after single versus tandem autologous stem cell rescue in high-risk neuroblastoma using a national administrative database.

Desai AV, Li Y, Getz K, Seif AE, Fisher B, Huang V, Aplenc R, Bagatell R.

Pediatr Blood Cancer. 2018 Dec;65(12):e27372. doi: 10.1002/pbc.27372. Epub 2018 Aug 1.

PMID:
30070014
15.

Lower glomerular filtration rate predicts increased hepatic and mucosal toxicity in myeloma patients treated with high-dose melphalan.

Tamaki M, Nakasone H, Gomyo A, Hayakawa J, Akahoshi Y, Harada N, Kusuda M, Ishihara Y, Kawamura K, Tanihara A, Sato M, Terasako-Saito K, Kameda K, Wada H, Kikuchi M, Kimura SI, Kako S, Kanda Y.

Int J Hematol. 2018 Oct;108(4):423-431. doi: 10.1007/s12185-018-2507-2. Epub 2018 Jul 23.

PMID:
30039440
16.

The effect of age on outcomes after isolated limb perfusion for advanced extremity malignancies.

Smith HG, Wilkinson MJ, Smith MJF, Strauss DC, Hayes AJ.

Eur J Cancer. 2018 Sep;100:46-54. doi: 10.1016/j.ejca.2018.04.014. Epub 2018 Jun 22.

18.

Heparin-induced thrombocytopenia and thrombosis during high dose melphalan and autologous stem cell transplantation.

Sarosiek S, Quillen K, Sloan JM, Brauneis D, Sanchorawala V.

Blood. 2018 Aug 16;132(7):755-757. doi: 10.1182/blood-2018-03-838672. Epub 2018 Jun 14. No abstract available.

PMID:
29903887
19.

High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity.

Noesslinger T, Panny M, Simanek R, Moestl M, Boehm A, Menschel E, Koller E, Keil F.

Eur J Haematol. 2018 Sep;101(3):326-331. doi: 10.1111/ejh.13102. Epub 2018 Aug 3.

PMID:
29799642
20.

Total retinal detachments due to retinoblastoma: Outcomes following intra-arterial chemotherapy/ophthalmic artery chemosurgery.

Rowlands MA, Mondesire-Crump I, Levin A, Mauguen A, Francis JH, Dunkel IJ, Brodie SE, Gobin YP, Abramson DH.

PLoS One. 2018 Apr 26;13(4):e0195395. doi: 10.1371/journal.pone.0195395. eCollection 2018.

Supplemental Content

Loading ...
Support Center